Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Zuckerman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Oncologist|May 25, 2006
Intravascular lymphoma: the oncologist's "great imitator"Dan Zuckerman, Rania Seliem, Ephraim Hochberg
Journal of Clinical Epidemiology|March 10, 2007
Veteran's affairs hospital discharge databases coded serious bacterial infections accuratelySebastian Schneeweiss, Ari Robicsek, Richard Scranton, et al.
The Oncologist|May 25, 2006
Teams: communication in multidisciplinary careRichard T Penson, Helena Kyriakou, Dan Zuckerman, et al.
Journal of Oncology Practice|December 29, 2016
Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation ReportMichael Neuss, Gabrielle Rocque, Dan Zuckerman, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPTPaolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Oncologist|May 25, 2006
Intravascular lymphoma: the oncologist's "great imitator"Dan Zuckerman, Rania Seliem, Ephraim Hochberg
Journal of Clinical Epidemiology|March 10, 2007
Veteran's affairs hospital discharge databases coded serious bacterial infections accuratelySebastian Schneeweiss, Ari Robicsek, Richard Scranton, et al.
The Oncologist|May 25, 2006
Teams: communication in multidisciplinary careRichard T Penson, Helena Kyriakou, Dan Zuckerman, et al.
Journal of Oncology Practice|December 29, 2016
Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation ReportMichael Neuss, Gabrielle Rocque, Dan Zuckerman, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPTPaolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Pageof 1